A randomized, controlled trial comparing the immunogenecity and safety of a 23‐valent pneumococcal polysaccharide vaccination to a repeated dose 13‐valent pneumococcal conjugate vaccination in kidney transplant recipients

• DOI: 10.1111/tid.13343
• Publication Date: 2020-05-30T21:19:20Z
• Authors: Mari Eriksson; Helena Käyhty; Heikki Saha; Mika Lahdenkari; Petri Koskinen; Heikki Mäkisalo; Veli‐Jukka Anttila
• Keywords: Pneumococcal polysaccharide vaccine; Pneumococcal Conjugate Vaccine

The risk of invasive pneumococcal disease is significant among solid organ transplant (SOT) recipients. optimal vaccination strategy for SOT patients not known.The potential kidney recipients in dialysis were randomized into two arms: to receive a 23-valent polysaccharide vaccine (PPV23) before transplantation or 13-valent conjugate (PCV13) and second dose PCV13 six months after the transplantation. Serotype-specific antibody concentrations opsonophagocytic activity (OPA) measured first (visits V1,V2) seven transplantation, example, V3,V4).Out 133 participants, 48 (PCV13 arm) 46 (PPV23 received transplant, 37 + both arms completed study. After vaccination, geometric mean (GMCs) arm significantly higher 9/13 serotypes OPA titers (GMTs) 4/13 serotypes. At V3, levels had declined but remained 7/13 vs V4, GMCs GMTs 12/13 arm. lower than at V2. There was no difference adverse effects. No vaccine-related allograft rejection detected.The immunogenicity better patients, revaccination with immunogenic safe.